The short version
- Why people research itLipolysis / fat loss without GH- or blood-sugar-related side effects.
- What the evidence isHuman trials exist, and reading them properly matters more here than almost anywhere in the Vault: every one gave it by mouth or by vein, none under the skin.
- What to watchHives or swelling beyond the site.
How AOD-9604 works
Modified C-terminal fragment of GH — stimulates lipolysis and inhibits lipogenesis without hitting IGF-1 or blood sugar.
Start with the name, because the name on this site's card is not quite this molecule. The card's aka is ‘HGH Fragment 176-191’.
Why a tyrosine. Tyrosine is the residue you add to a peptide when you need to radioiodinate it for a binding or pharmacokinetic assay. An N-terminal tyrosine on a fragment that does not otherwise have one is a laboratory handle, and it is a reasonable inference — stated here as inference, not as a published claim — that the molecule sold today carries a modification that was originally there to make the molecule measurable.
- Injectable
- Nasal
On the goal map: Direct lipolysis & adrenergic drive (Lose fat)
Research on AOD-96046 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Animal + limited human (modest).
Human clinical evidence
Human trials exist, and reading them properly matters more here than almost anywhere in the Vault: every one gave it by mouth or by vein, none under the skin. In a 12-week phase 2b trial, Metabolic Pharmaceuticals, 16 Dec 2004, not peer-reviewed). It is the trial usually reported as missing its weight endpoint, and we have not found its results in a peer-reviewed journal.
A missed scale-weight endpoint is routinely misread as 'it does nothing'. AOD-9604 is a lipolytic fragment with the growth-promoting and appetite-affecting regions deliberately removed — it was never going to suppress intake, and a compound that mobilizes fat without changing what you eat has little room to move a scale against placebo.
It was subsequently granted GRAS status as a food ingredient in the US. That is a statement about safety, not efficacy — but it is also why this is one of the most benign things in the fat-loss category.
Correlative data
Still widely used for fat loss, largely on the strength of the mechanism and the excellent safety record rather than the trial result. Reported experience is mild, which is consistent with what the trial found.
How the mechanism reads
The C-terminal fragment (176–191) of human growth hormone — the region associated with lipolytic activity, with the growth-promoting and glucose-antagonizing regions removed. That separation is the design goal and it works: it does not raise IGF-1 or affect blood glucose.
MechanisticRodent work shows stimulated lipolysis and inhibited lipogenesis. The honest reading is that the mechanism is real and the effect size in humans is small — which the phase 2b result already told us.
Experimental, animal or cell
Sources
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (studies METAOD001 to METAOD006).. J Endocrinol Metab 2013
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.. Horm Res 2000 · PMID 11146367
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.. Endocrinology 2001 · PMID 11713213
- Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604.. Drug Test Anal 2015 · PMID 25208511
- Vanhee C, Moens G, Deconinck E, De Beer JO. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.. Drug Test Anal 2014 · PMID 24976118
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.. Ann Clin Lab Sci 2015 · PMID 26275694
- Dominikowski A, Rekos Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchala M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne) 2026 · PMID 42395176
- Metabolic Pharmaceuticals Limited. Company announcements on the AOD9604 phase 2b obesity program, 2004-2007 (trial completion and outcome reported by press release, not in a peer-reviewed journal).. Company announcement, 2007
AOD-9604 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer, as a precaution for any GH-derived molecule.
- Past allergic reaction to a peptide injectable.
- Pregnancy or breastfeeding, which the six registered trials did not study.
- Under 18, where fragment effects on growth are untested.
What’s expected
- Mild lipolytic signaling without the IGF-1 rise of full GH.
- Minor redness or itch where it is placed.
- Occasional headache; the registered trial safety record was clean.
Watch for
- Hives or swelling beyond the site.
- A new joint that stays swollen or hot.
- Symptoms of high blood sugar such as excess thirst.
Labs that tell you it’s working
- IGF-1: should stay flat, which is the evidence it is not acting like growth hormone.
- Insulin (Fasting): the fragment was designed to leave glucose handling alone.
- HbA1c: confirms glucose control did not shift over months.
- Lipid Panel: triglycerides are the fat-mobilization readout.
Modified C-terminal fragment of GH (residues 177-191) with lipolytic effect and no IGF-1 or insulin-resistance action. PMID 11146367 PMID 11713213
Bloodwork to runHow you would know it is working: 6 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
AOD-9604 FAQ4 common questions
- Is AOD-9604 approved for human use?
- No. AOD-9604 is a research compound.
- What is AOD-9604 researched for?
- Lipolysis / fat loss without GH- or blood-sugar-related side effects.
- Which labs show whether it's doing anything?
- IGF-1; Insulin; HbA1c; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for AOD-9604: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





